Table of Contents
Hepatitis Research and Treatment
Volume 2016 (2016), Article ID 8325467, 8 pages
http://dx.doi.org/10.1155/2016/8325467
Clinical Study

Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy

1Department of General, Visceral and Transplantation Surgery, Charité Universitätsmedizin Berlin, Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany
2Institute of Medical Virology, Helmut-Ruska-Haus and Labor Berlin Charité-Vivantes GmbH, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

Received 30 November 2015; Accepted 8 March 2016

Academic Editor: Piero Luigi Almasio

Copyright © 2016 Fritz Klein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Berenguer, M. Prieto, J. M. Rayón et al., “Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation,” Hepatology, vol. 32, no. 4, part 1, pp. 852–858, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. L. M. Forman, J. D. Lewis, J. A. Berlin, H. I. Feldman, and M. R. Lucey, “The association between hepatitis C infection and survival after orthotopic liver transplantation,” Gastroenterology, vol. 122, no. 4, pp. 889–896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Gane, “The natural history of recurrent hepatitis C and what influences this,” Liver Transplantation, vol. 14, supplement 2, pp. S36–S44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Charlton, E. Seaberg, R. Wiesner et al., “Predictors of patient and graft survival following liver transplantation for hepatitis C,” Hepatology, vol. 28, no. 3, pp. 823–830, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Berenguer and D. Schuppan, “Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment,” Journal of Hepatology, vol. 58, no. 5, pp. 1028–1041, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Crespo, J. A. Carrión, M. Coto-Llerena et al., “Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation,” Journal of Gastroenterology, vol. 48, no. 6, pp. 762–769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Berenguer, A. Palau, V. Aguilera, J.-M. Rayón, F. S. Juan, and M. Prieto, “Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation,” American Journal of Transplantation, vol. 8, no. 3, pp. 679–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Berenguer, “Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 274–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Xirouchakis, C. Triantos, P. Manousou et al., “Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies,” Journal of Viral Hepatitis, vol. 15, no. 10, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Zeuzem, P. Andreone, S. Pol et al., “Telaprevir for retreatment of HCV infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2417–2428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Farnik, T. Zimmermann, E. Herrmann et al., “Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation,” Liver International, vol. 35, no. 1, pp. 176–183, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. G. McHutchison, M. P. Manns, A. J. Muir et al., “Telaprevir for previously treated chronic HCV infection,” The New England Journal of Medicine, vol. 362, no. 14, pp. 1292–1303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Charlton and E. Seaberg, “Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database,” Liver Transplantation and Surgery, vol. 5, no. 4, supplement 1, pp. S107–S114, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Garg, R. van Heeswijk, J. Eun Lee, K. Alves, P. Nadkarni, and X. Luo, “Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus,” Hepatology, vol. 54, no. 1, pp. 20–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Papadopoulos-Köhn, A. Achterfeld, A. Paul et al., “Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant,” Transplantation, vol. 99, no. 4, pp. 841–847, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. R. Burton Jr., J. G. O'Leary, E. C. Verna et al., “A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy,” Journal of Hepatology, vol. 61, no. 3, pp. 508–514, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Ikegami, T. Yoshizumi, M. Kato et al., “Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation,” Transplantation, vol. 98, no. 9, pp. 994–999, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Faisal, E. M. Yoshida, M. Bilodeau et al., “Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience,” Annals of Hepatology, vol. 13, no. 5, pp. 525–532, 2014. View at Google Scholar · View at Scopus
  20. P. Y. Kwo, P. S. Mantry, E. Coakley et al., “An interferon-free antiviral regimen for HCV after liver transplantation,” The New England Journal of Medicine, vol. 371, no. 25, pp. 2375–2382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. V. J. Desmet, M. Gerber, J. H. Hoofnagle, M. Manns, and P. J. Scheuer, “Classification of chronic hepatitis: diagnosis, grading and staging,” Hepatology, vol. 19, no. 6, pp. 1513–1520, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. B. R. Bacon, S. C. Gordon, E. Lawitz et al., “Boceprevir for previously treated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1207–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. R. Werner, D. P. Egetemeyr, U. M. Lauer et al., “Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data,” Liver Transplantation, vol. 18, no. 12, pp. 1464–1470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Coilly, B. Roche, J. Dumortier et al., “Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience,” Journal of Hepatology, vol. 60, no. 1, pp. 78–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Barritt IV and M. W. Fried, “Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus,” Gastroenterology, vol. 142, no. 6, pp. 1314–1323.e1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. L. Shiffman and R. Esteban, “Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?” Liver International, vol. 32, no. 1, pp. 54–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Benito, C. Sánchez-Parra, I. Maida et al., “Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir,” Antiviral Therapy, vol. 18, no. 5, pp. 709–715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Roche, M. Sebagh, M. L. Canfora et al., “Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis,” Liver Transplantation, vol. 14, no. 12, pp. 1766–1777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Morisco, M. Masarone, V. Rosato et al., “Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based “triple therapy” experience in southern Italy,” Reviews on Recent Clinical Trials, In press.
  30. C. R. Werner, D. P. Egetemeyr, S. Nadalin et al., “Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy,” Zeitschrift für Gastroenterologie, vol. 52, no. 1, pp. 27–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. E. C. Verna, V. Saxena, J. R. Burton et al., “Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: a multicenter study,” Transplantation, vol. 99, no. 8, pp. 1644–1651, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Gallegos-Orozco, A. Chervenak, E. Carey, B. Aqel, T. Byrne, L. Hartel et al., “Liver transplant center focused experience with peginterferon α-2a, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis,” Hepatology, vol. 2012, p. 218A, 2012. View at Google Scholar
  33. S. Pungpapong, B. A. Aqel, L. Koning et al., “Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation,” Liver Transplantation, vol. 19, no. 7, pp. 690–700, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. E. Sherman, S. L. Flamm, N. H. Afdhal et al., “Response-guided telaprevir combination treatment for hepatitis C virus infection,” New England Journal of Medicine, vol. 365, no. 11, pp. 1014–1024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Druyts, K. Thorlund, P. Wu et al., “Efficacy and safety of pegylated interferon Alfa-2a or Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 56, no. 7, pp. 961–967, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Zimner-Rapuch, N. Janus, G. Deray, and V. Launay-Vacher, “New therapies for hepatitis C: considerations in patients with renal impairment,” Drugs, vol. 74, no. 12, pp. 1307–1313, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Poordad, E. Lawitz, K. R. Reddy et al., “Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection—a randomized trial,” Gastroenterology, vol. 145, no. 5, pp. 1035–1044.e5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Susser, J. Vermehren, N. Forestier et al., “Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir,” Journal of Clinical Virology, vol. 52, no. 4, pp. 321–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Chalasani, C. Manzarbeitia, P. Ferenci et al., “Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials,” Hepatology, vol. 41, no. 2, pp. 289–298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Samuel, T. Bizollon, C. Feray et al., “Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study,” Gastroenterology, vol. 124, no. 3, pp. 642–650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. U. Chatterji, M. Bobardt, S. Selvarajah et al., “The isomerase active site of cyclophilin A is critical for hepatitis C virus replication,” The Journal of Biological Chemistry, vol. 284, no. 25, pp. 16998–17005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Cescon, G. L. Grazi, A. Cucchetti et al., “Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation,” Liver Transplantation, vol. 15, no. 7, pp. 782–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Hézode, H. Fontaine, C. Dorival et al., “Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890,” Journal of Hepatology, vol. 59, no. 3, pp. 434–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Y. Kwo and M. B. Badshah, “New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease,” Current Opinion in Organ Transplantation, vol. 20, no. 3, pp. 235–241, 2015. View at Publisher · View at Google Scholar
  46. A. H. L. Yau and E. M. Yoshida, “Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral, interferon-free antiviral regimens: a concise review,” Canadian Journal of Gastroenterology and Hepatology, vol. 28, no. 8, pp. 445–451, 2014. View at Google Scholar · View at Scopus
  47. R. J. Fontana, E. A. Hughes, M. Bifano et al., “Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C,” American Journal of Transplantation, vol. 13, no. 6, pp. 1601–1605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Charlton, E. Gane, M. P. Manns et al., “Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation,” Gastroenterology, vol. 148, no. 1, pp. 108–117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres et al., “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection,” The New England Journal of Medicine, vol. 370, no. 3, pp. 211–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. M. P. Curry, X. Forns, R. T. Chung et al., “Sofosbuvir and ribavirin prevent recurrence of hcv infection after liver transplantation: an open-label study,” Gastroenterology, vol. 148, no. 1, pp. 100–107.e1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. European Association for Study of Liver, “EASL clinical practice guidelines: management of hepatitis C virus infection,” Journal of Hepatology, vol. 60, no. 2, pp. 392–420, 2014. View at Publisher · View at Google Scholar